In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI)

an adult mechanical ventilation model

Alejandro Rodríguez, María Cabrera, Luis F. Reyes, María Bodí, Sandra Trefler, Laura Canadell, Diego Barahona, Stepham Ehrmann, Ignacio Martin-Loeches, Marcos Restrepo, Laurent Vecellio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The delivery profile of Aztreonam lysine (AZLI) during mechanical ventilation (MV) is unknown. We evaluated the amount of AZLI drug delivered using an in vitro model of adult MV. Methods: An adult lung model designed to mimic current clinical practice was used. Both nebulizers were placed before a Y-piece and 4 settings were tested: A) Aeroneb solo® [AS] with a t-piece; B) AS with the spacer; C) M-Neb® [MN] with a t-piece and D) MN with the spacer. Performance was evaluated in terms of: 1) Mass median aerodynamic diameter (MMAD); 2) Geometric standard deviation (GSD), 3) Fine particle dose (FPD), 4) Fine particle fraction (FPF), 5) Inhalable mass (IM), and 6) Recovery rate (RR). Results: Both devices showed an adequate delivery of AZLI during MV, with MMAD between 2.4–2.5 µm and 87% of FPF. The FPD (38.8 and 31.7), IM (44.8 and 36.1) and RR (30 and 24) were similar for AS and MN respectively. Nebulizer aerosol delivery increased (50 and 70% respectively) for both nebulizers when using the spacer. Conclusion: Both AS and MN showed a good aerosol delivery profile for AZLI during in vitro mechanical ventilation. Better aerosol delivery performance was obtained using the spacer.

Original languageEnglish (US)
Pages (from-to)1447-1453
Number of pages7
JournalExpert Opinion on Drug Delivery
Volume14
Issue number12
DOIs
StatePublished - Dec 2 2017

Fingerprint

Aztreonam
Aerosols
Artificial Respiration
Lysine
Nebulizers and Vaporizers
Equipment and Supplies
Lung
In Vitro Techniques
Pharmaceutical Preparations

Keywords

  • aerosol delivery
  • Aztreonam lysine
  • in vitro model
  • mechanical ventilation
  • nebulized antibiotic

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Rodríguez, A., Cabrera, M., Reyes, L. F., Bodí, M., Trefler, S., Canadell, L., ... Vecellio, L. (2017). In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI): an adult mechanical ventilation model. Expert Opinion on Drug Delivery, 14(12), 1447-1453. https://doi.org/10.1080/17425247.2017.1393411

In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI) : an adult mechanical ventilation model. / Rodríguez, Alejandro; Cabrera, María; Reyes, Luis F.; Bodí, María; Trefler, Sandra; Canadell, Laura; Barahona, Diego; Ehrmann, Stepham; Martin-Loeches, Ignacio; Restrepo, Marcos; Vecellio, Laurent.

In: Expert Opinion on Drug Delivery, Vol. 14, No. 12, 02.12.2017, p. 1447-1453.

Research output: Contribution to journalArticle

Rodríguez, A, Cabrera, M, Reyes, LF, Bodí, M, Trefler, S, Canadell, L, Barahona, D, Ehrmann, S, Martin-Loeches, I, Restrepo, M & Vecellio, L 2017, 'In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI): an adult mechanical ventilation model', Expert Opinion on Drug Delivery, vol. 14, no. 12, pp. 1447-1453. https://doi.org/10.1080/17425247.2017.1393411
Rodríguez, Alejandro ; Cabrera, María ; Reyes, Luis F. ; Bodí, María ; Trefler, Sandra ; Canadell, Laura ; Barahona, Diego ; Ehrmann, Stepham ; Martin-Loeches, Ignacio ; Restrepo, Marcos ; Vecellio, Laurent. / In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI) : an adult mechanical ventilation model. In: Expert Opinion on Drug Delivery. 2017 ; Vol. 14, No. 12. pp. 1447-1453.
@article{e403afecf4074527a90f925315ec81e9,
title = "In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI): an adult mechanical ventilation model",
abstract = "Background: The delivery profile of Aztreonam lysine (AZLI) during mechanical ventilation (MV) is unknown. We evaluated the amount of AZLI drug delivered using an in vitro model of adult MV. Methods: An adult lung model designed to mimic current clinical practice was used. Both nebulizers were placed before a Y-piece and 4 settings were tested: A) Aeroneb solo{\circledR} [AS] with a t-piece; B) AS with the spacer; C) M-Neb{\circledR} [MN] with a t-piece and D) MN with the spacer. Performance was evaluated in terms of: 1) Mass median aerodynamic diameter (MMAD); 2) Geometric standard deviation (GSD), 3) Fine particle dose (FPD), 4) Fine particle fraction (FPF), 5) Inhalable mass (IM), and 6) Recovery rate (RR). Results: Both devices showed an adequate delivery of AZLI during MV, with MMAD between 2.4–2.5 µm and 87{\%} of FPF. The FPD (38.8 and 31.7), IM (44.8 and 36.1) and RR (30 and 24) were similar for AS and MN respectively. Nebulizer aerosol delivery increased (50 and 70{\%} respectively) for both nebulizers when using the spacer. Conclusion: Both AS and MN showed a good aerosol delivery profile for AZLI during in vitro mechanical ventilation. Better aerosol delivery performance was obtained using the spacer.",
keywords = "aerosol delivery, Aztreonam lysine, in vitro model, mechanical ventilation, nebulized antibiotic",
author = "Alejandro Rodr{\'i}guez and Mar{\'i}a Cabrera and Reyes, {Luis F.} and Mar{\'i}a Bod{\'i} and Sandra Trefler and Laura Canadell and Diego Barahona and Stepham Ehrmann and Ignacio Martin-Loeches and Marcos Restrepo and Laurent Vecellio",
year = "2017",
month = "12",
day = "2",
doi = "10.1080/17425247.2017.1393411",
language = "English (US)",
volume = "14",
pages = "1447--1453",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - In vitro evaluation of aerosol delivery of aztreonam lysine (AZLI)

T2 - an adult mechanical ventilation model

AU - Rodríguez, Alejandro

AU - Cabrera, María

AU - Reyes, Luis F.

AU - Bodí, María

AU - Trefler, Sandra

AU - Canadell, Laura

AU - Barahona, Diego

AU - Ehrmann, Stepham

AU - Martin-Loeches, Ignacio

AU - Restrepo, Marcos

AU - Vecellio, Laurent

PY - 2017/12/2

Y1 - 2017/12/2

N2 - Background: The delivery profile of Aztreonam lysine (AZLI) during mechanical ventilation (MV) is unknown. We evaluated the amount of AZLI drug delivered using an in vitro model of adult MV. Methods: An adult lung model designed to mimic current clinical practice was used. Both nebulizers were placed before a Y-piece and 4 settings were tested: A) Aeroneb solo® [AS] with a t-piece; B) AS with the spacer; C) M-Neb® [MN] with a t-piece and D) MN with the spacer. Performance was evaluated in terms of: 1) Mass median aerodynamic diameter (MMAD); 2) Geometric standard deviation (GSD), 3) Fine particle dose (FPD), 4) Fine particle fraction (FPF), 5) Inhalable mass (IM), and 6) Recovery rate (RR). Results: Both devices showed an adequate delivery of AZLI during MV, with MMAD between 2.4–2.5 µm and 87% of FPF. The FPD (38.8 and 31.7), IM (44.8 and 36.1) and RR (30 and 24) were similar for AS and MN respectively. Nebulizer aerosol delivery increased (50 and 70% respectively) for both nebulizers when using the spacer. Conclusion: Both AS and MN showed a good aerosol delivery profile for AZLI during in vitro mechanical ventilation. Better aerosol delivery performance was obtained using the spacer.

AB - Background: The delivery profile of Aztreonam lysine (AZLI) during mechanical ventilation (MV) is unknown. We evaluated the amount of AZLI drug delivered using an in vitro model of adult MV. Methods: An adult lung model designed to mimic current clinical practice was used. Both nebulizers were placed before a Y-piece and 4 settings were tested: A) Aeroneb solo® [AS] with a t-piece; B) AS with the spacer; C) M-Neb® [MN] with a t-piece and D) MN with the spacer. Performance was evaluated in terms of: 1) Mass median aerodynamic diameter (MMAD); 2) Geometric standard deviation (GSD), 3) Fine particle dose (FPD), 4) Fine particle fraction (FPF), 5) Inhalable mass (IM), and 6) Recovery rate (RR). Results: Both devices showed an adequate delivery of AZLI during MV, with MMAD between 2.4–2.5 µm and 87% of FPF. The FPD (38.8 and 31.7), IM (44.8 and 36.1) and RR (30 and 24) were similar for AS and MN respectively. Nebulizer aerosol delivery increased (50 and 70% respectively) for both nebulizers when using the spacer. Conclusion: Both AS and MN showed a good aerosol delivery profile for AZLI during in vitro mechanical ventilation. Better aerosol delivery performance was obtained using the spacer.

KW - aerosol delivery

KW - Aztreonam lysine

KW - in vitro model

KW - mechanical ventilation

KW - nebulized antibiotic

UR - http://www.scopus.com/inward/record.url?scp=85031898901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031898901&partnerID=8YFLogxK

U2 - 10.1080/17425247.2017.1393411

DO - 10.1080/17425247.2017.1393411

M3 - Article

VL - 14

SP - 1447

EP - 1453

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 12

ER -